Advanced search
Publication Cover
Epigenomics Volume 5, 2013 - Issue 4
Submit an article Journal homepage
195
Views
0
CrossRef citations to date
0
Altmetric
Special Report

Histone Modifications: Implications in Renal Cell Carcinoma

Swathi Ramakrishnan1 Roswell Park Cancer Institute, Department of Cancer Pathology & Prevention, Grace Cancer Drug Center, Buffalo, NY, USA;2 Roswell Park Cancer Institute, Genitourinary Program, Grace Cancer Drug Center, Buffalo, NY, USAView further author information
,
Leigh Ellis2 Roswell Park Cancer Institute, Genitourinary Program, Grace Cancer Drug Center, Buffalo, NY, USA;3 Roswell Park Cancer Institute, Department of Pharmacology & Therapeutics, Grace Cancer Drug Center, Buffalo, NY, USAView further author information
&
Roberto Pili4 Roswell Park Cancer Institute, Department of Medicine, Grace Cancer Drug Center, Buffalo, NY, USA;2 Roswell Park Cancer Institute, Genitourinary Program, Grace Cancer Drug Center, Buffalo, NY, USA;4 Roswell Park Cancer Institute, Department of Medicine, Grace Cancer Drug Center, Buffalo, NY, USACorrespondence[email protected]
View further author information
Pages 453-462 | Published online: 29 Jul 2013

References

  • Ellis L , AtadjaPW, JohnstoneRW. Epigenetics in cancer: targeting chromatin modifications. Mol. Cancer Ther.8(6) , 1409–1420 (2009).
  • Hake SB , XiaoA, AllisCD. Linking the epigenetic ‘language‘ of covalent histone modifications to cancer. Br. J. Cancer90(4) , 761–769 (2004).
  • Wang GG , AllisCD, ChiP. Chromatin remodeling and cancer, part I: covalent histone modifications. Trends Mol. Med.13(9) , 363–372 (2007).
  • Ellinger J , KahlP, MertensC et al. Prognostic relevance of global histone H3 lysine 4 (H3K4) methylation in renal cell carcinoma. Int. J. Cancer 127(10) , 2360–2366 (2010).
  • Turner BM . Histone acetylation and an epigenetic code. BioEssays22(9) , 836–845 (2000).
  • Iizuka M , SmithMM. Functional consequences of histone modifications. Curr. Opin Genet. Dev.13(2) , 154–160 (2003).
  • Grant P . A tale of histone modifications. Genome Biol.2(4) , 3.1–3.6 (2001).
  • Milne JC , DenuJM. The Sirtuin family: therapeutic targets to treat diseases of aging. Curr. Opin Chem. Biol.12(1) , 11–17 (2008).
  • Bolden JE , PeartMJ, JohnstoneRW. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov.5(9) , 769–784 (2006).
  • Cortez CC , JonesPA. Chromatin, cancer and drug therapies. Mutat. Res.647(1–2) , 44–51 (2008).
  • Greiner D , BonaldiT, EskelandR, RoemerE, ImhofA. Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3–9. Nat. Chem. Biol.1(3) , 143–145 (2005).
  • Zeisberg M , KalluriR. The role of epithelial-to-mesenchymal transition in renal fibrosis. J. Mol. Med. (Berl.)82(3) , 175–181 (2004).
  • Kleer CG , CaoQ, VaramballyS et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl Acad. Sci. USA 100(20) , 11606–11611 (2003).
  • Sato A , AsanoT, ItoK, SumitomoM, AsanoT. Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically. BJU Int.109(8) , 1258–1268 (2011).
  • Ozdag H , TeschendorffA, AhmedA et al. Differential expression of selected histone modifier genes in human solid cancers. BMC Genomics 7(1) , 90 (2006).
  • Pradhan S , ChinHG, Estève P-O, Jacobsen SE. SET7/9 mediated methylation of non‑histone proteins in mammalian cells. Epigenetics4(6) , 383–387 (2009).
  • Chi P , AllisCD, WangGG. Covalent histone modifications – miswritten, misinterpreted and mis-erased in human cancers. Nat. Rev. Cancer10(7) , 457–469 (2010).
  • Di Stefano L , DysonNJ. The emerging roles for histone demethylases in the modulation of signaling pathways. Biomol. Concepts4(1) , 13–27 (2013).
  • Berry WL , JanknechtR. KDM4/JMJD2 histone demethylases: epigenetic regulators in cancer cells. Cancer Res.73(10) , 2936–2942 (2013).
  • Nightingale KP , O‘NeillLP, TurnerBM. Histone modifications: signalling receptors and potential elements of a heritable epigenetic code. Curr. Opin Genet. Dev.16(2) , 125–136 (2006).
  • He H , LehmingN. Global effects of histone modifications. Brief. Funct. Genomic. Proteomic.2(3) , 234–243 (2003).
  • Bártová E , KrejčíJ, HarničarováA, GaliováG, KozubekS. Histone modifications and nuclear architecture: a review. J. Histochem. Cytochem.56(8) , 711–721 (2008).
  • Li E . Chromatin modification and epigenetic reprogramming in mammalian development. Nat. Rev. Genet.3(9) , 662–673 (2002).
  • Mahalingam D , MedinaEC, EsquivelJA et al. Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels. Clin. Cancer Res. 16(1) , 141–153 (2010).
  • Latham JA , DentSYR. Cross-regulation of histone modifications. Nat. Struct. Mol. Biol.14(11) , 1017–1024 (2007).
  • Cha TL , ChuangMJ, WuST et al. Dual degradation of Aurora A and B kinases by the histone deacetylase inhibitor LBH589 induces G2-M arrest and apoptosis of renal cancer cells. Clin. Cancer Res. 15(3) , 840–850 (2009).
  • Cheung P , AllisCD, Sassone-CorsiP. Signaling to chromatin through histone modifications. Cell103(2) , 263–271 (2000).
  • Peterson CL , LanielMA. Histones and histone modifications. Curr. Biol.14(14) , R546–R551 (2004).
  • Francois F . DNA methylation and histone modifications: teaming up to silence genes. Curr. Opin Genet. Dev.15(5) , 490–495 (2005).
  • Cea M , SonciniD, FruscioneF et al. Synergistic interactions between HDAC and Sirtuin inhibitors in human leukemia cells. PLoS One 6(7) , e22739 (2011).
  • Lara E , MaiA, CalvaneseV et al. Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect. Oncogene 28(8) , 1168–1168 (2009).
  • Choi K -C, Jung MG, Lee YH et al. Epigallocatechin-3-gallate, a histone acetyltransferase inhibitor, inhibits EBV-induced B lymphocyte transformation via suppression of RelA acetylation. Cancer Res.69(2) , 583–592 (2009).
  • Cui L , MiaoJ, FuruyaT et al. Histone acetyltransferase inhibitor anacardic acid causes changes in global gene expression during in vitro plasmodium falciparum development. Eukaryot. Cell 7(7) , 1200–1210 (2008).
  • Furdas SD , KannanS, SipplW, JungM. Small molecule inhibitors of histone acetyltransferases as epigenetic tools and drug candidates. Arch. Pharm. (Weinheim)345(1) , 7–21 (2012).
  • Wagner T , JungM. New lysine methyltransferase drug targets in cancer. Nat. Biotechnol.30(7) , 622–623 (2012).
  • Zagni C , ChiacchioU, RescifinaA. Histone methyltransferase inhibitors: novel epigenetic agents for cancer treatment. Curr. Med. Chem.20(2) , 167–185 (2013).
  • Lohse B , KristensenJL, KristensenLH et al. Inhibitors of histone demethylases. Bioorg. Med. Chem. 19(12) , 3625–3636 (2011).
  • Sayegh J , CaoJ, ZouMR et al. Identification of small molecule inhibitors of jumonji AT-rich interactive domain 1B (JARID1B) histone demethylase by a sensitive high‑throughput screen. J. Biol. Chem. 288(13) , 9408–9417 (2013).
  • Fraga MF , BallestarE, Villar-GareaA et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet. 37(4) , 391–400 (2005).
  • Metzger E , WissmannM, YinN et al. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 437(7057) , 436–439 (2005).
  • Kurdistani SK . Histone modifications as markers of cancer prognosis: a cellular view. Br. J. Cancer97(1) , 1–5 (2007).
  • Cheng H -L, Mostoslavsky R, Saito SI et al. Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc. Natl Acad. Sci. USA100(19) , 10794–10799 (2003).
  • Li M , LuoJ, BrooksCL, GuW. Acetylation of p53 inhibits its ubiquitination by Mdm2. J. Biol. Chem.277(52) , 50607–50611 (2002).
  • Roy S , PackmanK, JeffreyR, TenniswoodM. Histone deacetylase inhibitors differentially stabilize acetylated p53 and induce cell cycle arrest or apoptosis in prostate cancer cells. Cell Death Differ.12(5) , 482–491 (2005).
  • Kai L , SamuelSK, LevensonAS. Resveratrol enhances p53 acetylation and apoptosis in prostate cancer by inhibiting MTA1/NuRD complex. Int. J. Cancer126(7) , 1538–1548 (2010).
  • Qian DZ , KachhapSK, CollisSJ et al. Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1α. Cancer Res. 66(17) , 8814–8821 (2006).
  • Beyer S , KristensenMM, JensenKS, JohansenJV, StallerP. The histone demethylases JMJD1A and JMJD2B are transcriptional targets of hypoxia-inducible factor HIF. J. Biol. Chem.283(52) , 36542–36552 (2008).
  • Krieg AJ , RankinEB, ChanD, RazorenovaO, FernandezS, GiacciaAJ. Regulation of the histone demethylase JMJD1A by hypoxia-inducible factor 1{alpha} enhances hypoxic gene expression and tumor growth. Mol. Cell. Biol.30(1) , 344–353 (2010).
  • Guo X , ShiM, SunL et al. The expression of histone demethylase JMJD1A in renal cell carcinoma. Neoplasma 58(2) , 153–157 (2011).
  • Niu X , ZhangT, LiaoL et al. The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C. Oncogene 31(6) , 776–786 (2012).
  • Yoshikawa M , HishikawaK, MarumoT, FujitaT. Inhibition of histone deacetylase activity suppresses epithelial-to-mesenchymal transition induced by TGF-β1 in human renal epithelial cells. J. Am. Soc. Nephrol.18(1) , 58–65 (2007).
  • Vanoosten RL , EarelJK Jr, Griffith TS. Enhancement of Ad5-TRAIL cytotoxicity against renal cell carcinoma with histone deacetylase inhibitors. Cancer Gene Ther.13(6) , 628–632 (2006).
  • Verheul HMW , SalumbidesB, Van Erp K et al. Combination strategy targeting the hypoxia inducible factor-1α with mammalian target of rapamycin and histone deacetylase inhibitors. Clin. Cancer Res.14(11) , 3589–3597 (2008).
  • Kanao K , MikamiS, MizunoR, ShinojimaT, MuraiM, OyaM. Decreased acetylation of histone H3 in renal cell carcinoma: a potential target of histone deacetylase inhibitors. J. Urol.180(3) , 1131–1136 (2008).
  • Duns G , Van Den Berg E, Van Duivenbode I et al. Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma. Cancer Res.70(11) , 4287–4291 (2010).
  • Dalgliesh GL , FurgeK, GreenmanC et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463(7279) , 360–363 (2010).
  • Varela I , TarpeyP, RaineK et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469(7331) , 539–542 (2011).
  • Hakimi AA , Chen Y-B, Wren J et al. Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. Eur. Urol.63(5) , 848–854 (2012).
  • Sakurai T , BilimVN, UgolkovAV et al. The enhancer of zeste homolog 2 (EZH2), a potential therapeutic target, is regulated by miR-101 in renal cancer cells. Biochem. Biophys. Res. Commun. 422(4) , 607–614 (2012).
  • Shen Y , GuoX, WangY et al. Expression and significance of histone H3K27 demethylases in renal cell carcinoma. BMC Cancer 12(1) , 470 (2012).
  • Richon V , ZhouX, RifkindR, MarksP. Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers. Blood Cells Mol. Dis.27(1) , 260–264 (2001).
  • Ajiro K , NishimotoT. Specific site of histone H3 phosphorylation related to the maintenance of premature chromosome condensation. Evidence for catalytically induced interchange of the subunits. J. Biol. Chem.260(29) , 15379–15381 (1985).
  • Tikoo K , LauSS, MonksTJ. Histone H3 phosphorylation is coupled to poly-(ADP-Ribosylation) during reactive oxygen species‑induced cell death in renal proximal tubular epithelial cells. Mol. Pharmacol.60(2) , 394–402 (2001).
  • Nan X , NgHH, JohnsonCA et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393(6683) , 386–389 (1998).
  • Majid S , DarAA, AhmadAE et al. BTG3 tumor suppressor gene promoter demethylation, histone modification and cell cycle arrest by genistein in renal cancer. Carcinogenesis 30(4) , 662–670 (2009).
  • Touma SE , GoldbergJS, MoenchP et al. Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model. Clin. Cancer Res. 11(9) , 3558–3566 (2005).
  • Wang X -F, Qian DZ, Ren M et al. Epigenetic modulation of retinoic acid receptor β2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma. Clin. Cancer Res.11(9) , 3535–3542 (2005).
  • Minardi D , LucariniG, FilosaA et al. Do DNA-methylation and histone acetylation play a role in clear cell renal carcinoma? Analysis of radical nephrectomy specimens in a long-term follow-up. Int. J. Immunopathol. Pharmacol. 24(1) , 149–158 (2011).
  • Rogenhofer S , KahlP, HolzapfelS, Von Ruecker A, Mueller SC, Ellinger J. Decreased levels of histone H3K9me1 indicate poor prognosis in patients with renal cell carcinoma. Anticancer Res.32(3) , 879–886 (2012).
  • Mosashvilli D , KahlP, MertensC et al. Global histone acetylation levels: prognostic relevance in patients with renal cell carcinoma. Cancer Sci. 101(12) , 2664–2669 (2010).
  • Seligson DB , HorvathS, McbrianMA et al. Global levels of histone modifications predict prognosis in different cancers. Am. J. Pathol. 174(5) , 1619–1628 (2009).
  • Xia W , NagaseS, MontiaAG et al. BAF180 is a critical regulator of p21 induction and a tumor suppressor mutated in breast cancer. Cancer Res. 68(6) , 1667–1674 (2008).
  • Pawłowski R , MühlSM, SulserT, KrekW, MochH, SchramlP. Loss of PBRM1 expression is associated with renal cell carcinoma progression. Int. J. Cancer132(2) , E11–E17 (2013).
  • Gerlinger M , RowanAJ, HorswellS et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366(10) , 883–892 (2012).
  • Van Den Berg A , BuysCHCM. Involvement of multiple loci on chromosome 3 in renal cell cancer development. Genes Chromosomes Cancer19(2) , 59–76 (1997).
  • Hakimi AA , OstrovnayaI, RevaB et al. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Clin. Cancer Res. 19(12) , 3259–3267 (2013).
  • Bernt Kathrin M , ZhuN, Sinha Amit U et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell20(1) , 66–78 (2011).
  • Pajtler K , WeingartenC, ThorT et al. The KDM1A histone demethylase is a promising new target for the epigenetic therapy of medulloblastoma. Acta Neuropathol. Comm. 1(1) , 19 (2013).
  • Koh CM , IwataT, ZhengQ, BethelC, YegnasubramanianS, De Marzo AM. Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms. Oncotarget2(9) , 669–683 (2011).
  • Mccabe MT , OttHM, GanjiG et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492(7427) , 108–112 (2012).
  • Chan K -M, Fang D, Gan H et al. The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. Genes Dev.27(9) , 985–990 (2013).
  • Jones J , JuengelE, MickuckyteA et al. Valproic acid blocks adhesion of renal cell carcinoma cells to endothelium and extracellular matrix. J. Cell. Mol. Med. 13(8b) , 2342–2352 (2009).
  • Kato Y , YoshimuraK, ShinT et al. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma. Clin. Cancer Res. 13(15) , 4538–4546 (2007).
  • Rogenhofer S , KahlP, MertensC et al. Global histone H3 lysine 27 (H3K27) methylation levels and their prognostic relevance in renal cell carcinoma. BJU Int. 109(3) , 459–465 (2011).
  • Fritzsche F , WeichertW, RoskeA et al. Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer. BMC Cancer 8(1) , 381 (2008).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.